menu
    • menu
    [{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA Topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merrimack Pharmaceuticals \/ Merrimack Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Merrimack Pharmaceuticals \/ Merrimack Pharmaceuticals"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Irinotecan Hydrochloride","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Merrimack Pharmaceuticals","amount2":1.03,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"Infusion","sponsorNew":"Merrimack Pharmaceuticals \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Merrimack Pharmaceuticals \/ Ipsen"}]

    Find Clinical Drug Pipeline Developments & Deals by Merrimack Pharmaceuticals

    Menu

    Merrimack Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Merrimack Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Merrimack Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Ipsen

                            Deal Size : $1,025.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Merrimack Receives $225 Million Milestone Payment from Ipsen

                            Details : Ipsen acquired exclusive commercialization rights for Onivyde, an encapsulated formulation of irinotecan as a first-line treatment for metastatic adenocarcinoma of the pancreas in the US.

                            Brand Name : Onivyde

                            Molecule Type : Small molecule

                            Upfront Cash : $575.0 million

                            March 27, 2024

                            Lead Product(s) : Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Ipsen

                            Deal Size : $1,025.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Merrimack Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Merrimack Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Ipsen

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line ...

                            Details : The press release indicates that the “the primary endpoint OS was not met in patients treated with Onivyde (irinotecan) versus topotecan. However, a doubling of the secondary endpoint of objective response rate (ORR) in favor of Onivyde was observed.

                            Brand Name : Onivyde

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 03, 2022

                            Lead Product(s) : Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Ipsen

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth